Eisai and BioArctic Neuroscience Enter Exclusive Licensing Agreement with Novel Antibody Treatment for Alzheimer's Disease.
BAN2401 is the result of a strategic research alliance between Eisai and BioArctic initiated in 2005 to identify a potential immunotherapy for Alzheimer's disease. The research is based on the Arctic mutation of amyloid beta-peptide, discovered by Prof. Lannfelt at Uppsala University, which causes familial Alzheimer's disease.
BAN2401 is a humanized monoclonal antibody which selectively recognizes amyloid beta-peptide protofibrils, a form of soluble aggregate of amyloid beta-peptide believed to play a key role in the development of Alzheimer's disease. The antibody is currently in pre-clinical development and Eisai aims to develop a novel treatment for Alzheimer's disease using this antibody.
The licensing agreement for BAN2401, together with the gamma secretase modulator E2012 developed in-house by Eisai, allows the Company to pursue parallel approaches to developing next-generation treatments for Alzheimer's disease based on a small molecule compound and immunotherapy.
As a pioneer in Alzheimer's disease treatment, having discovered and developed Aricept(R)(donepezil hydrochloride), Eisai aims to accelerate the development of a new generation of treatments for Alzheimer's disease through in-house activities and alliances with outside organizations.
 BioArctic Neuroscience AB
BioArctic Neuroscience is a biopharmaceutical company established in 2003 with the aim of commercializing the research in Alzheimer's disease carried out by the internationally renowned researcher Prof. Lannfelt at Uppsala University.
Pathogenesis of Alzheimer's disease and amyloid beta-peptide protofibrils
Accumulation of amyloid beta-peptide in the brain is believed to play a key role in the development of Alzheimer's disease. Pathologically, the accumulation is found as senile plaques containing aggregated insoluble amyloid beta-peptide fibrils. It is described that the toxic species causing Alzheimer's disease are the precursor forms of insoluble amyloid beta-peptide fibrils, the soluble amyloid beta-peptide aggregates including amyloid beta-peptide protofibrils.
3. Immunotherapy for Alzheimer's disease
As immunotherapies for Alzheimer's disease, there exist vaccine therapies that use amyloid beta-peptide to induce anti-amyloid beta-peptide immunoresponses, and antibody therapies that administrate monoclonal antibodies targeting amyloid beta-peptide. BAN2401 targets brain amyloid beta-peptide protofibrils by applying BioArctic Neuroscience's technology and it can efficiently eliminate amyloid beta-peptide species causing Alzheimer's disease.
4. Arctic mutation in amyloid beta-peptide
The Arctic mutation, which is one amino acid substitution in the amyloid beta-peptide peptide was discovered by Prof. Lannfelt at Uppsala University. This mutation causes familial Alzheimer's disease.
About Eisai Co., Ltd.
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care company that discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 8,000 people worldwide. For more information, please visit http://www.eisai.co.jp.
Source: Eisai Co., Ltd.
Corporate Communications Department Eisai Co., Ltd. Tel: +81-3-3817-5120
Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 4, 2007|
|Previous Article:||Showa Denko K.K. (SDK) to Introduce Corporate Fellow System.|
|Next Article:||Sharp Develops Industry's First Tuner Module Compatible with China Digital Television Terrestrial Broadcasting System Standard.|